Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

Soumitri Barua, Robert A. Greenwald, Jason Grebely et al. · Annals of Internal Medicine · 2015 · 397 citations · Full text

Pharmacy, Health Policy, Pharmaceutical Policy +17

Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

Gregory J. Dore, Frederick L. Altice, Alain H. Litwin et al. · Annals of Internal Medicine · 2016 · 363 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Ira M. Jacobson, Eric Lawitz, Edward Gane et al. · Gastroenterology · 2017 · 239 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe

Alison D. Marshall, Evan B. Cunningham, Stine Nielsen et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 150 citations · Full text

Pharmacy, Infectious Diseases, Pharmaceutical Policy +13

Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada

Kate Mason, Zoë Dodd, Mary Guyton et al. · International Journal of Drug Policy · 2017 · 126 citations · Full text

Pharmacy, Community Health, Pharmacotherapy +17